Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2012

Bioinformatics Tools for Clinical Sequencing

  • Laboratory Corporation of America (LabCorp) reported their license to deploy Ingenuity System's clinical content and applications to rapidly review and annotate clinically relevant sequence variations. This new system will leverage the Ingenuity Knowledge Base of biomedical content, including an up-to-date database of all human disease phenotype-associated variants. The variant knowledge base will be delivered through a cloud-based application for variant interpretation.

    "Next-generation sequencing is poised to transform the molecular diagnostic market, but the opportunity is gated by the urgent need for an optimized and scalable solution for interpreting and scoring clinical variants," says Jake Leschly, CEO of Ingenuity Systems. "Ingenuity has developed the information infrastructure, curated content, and cloud-based applications to address this need, and we are very fortunate to be able to partner with LabCorp to further evolve the solution and be part of their vision and strategy for molecular diagnostics."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »